Goldman Sachs analyst Richard Ramsden maintains Morgan Stanley (NYSE:MS) with a Buy and raises the price target from $85 to $94.
Strategic Fit of ACP-101 Promises Future Revenue Growth for Acadia Pharmaceuticals: Analyst
Tuesday, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101 (intranasal carbetocin), for hyperphagia (a false and unrelenting state of starvation)